Revumenib
Blinatumomab
M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Blinatumomab cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Blinatumomab M.D. Anderson Cancer Center | Phase 2 | B |
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 2 | CCC |
Inotuzumab Ozogamicin The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
METHOTREXATE M.D. Anderson Cancer Center | Phase 2 | CCC |
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | CCC |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 2 | CCC |
Olverembatinib M.D. Anderson Cancer Center | Phase 2 | CCC |
PREDNISONE TABLETS M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
Revumenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →